Detail akcie Crescent Biophar Rg online

Business Summary: Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Crescent Biopharma Inc revenues was not reported. Net loss increased 59% to $48.7M. Higher net loss reflects researcg and development expense balanc increase from $9.3M to $24.5M (expense), General and administrative expense increase of 79% to $5.2M (expense), Labor & Related Expenses in R&D increase of 43% to $5.4M (expense).